Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Accounts Payables (2023 - 2025)

Mangoceuticals' Accounts Payables history spans 3 years, with the latest figure at $526964.0 for Q3 2025.

  • For Q3 2025, Accounts Payables fell 25.52% year-over-year to $526964.0; the TTM value through Sep 2025 reached $526964.0, down 25.52%, while the annual FY2024 figure was $837501.0, 494.96% up from the prior year.
  • Accounts Payables for Q3 2025 was $526964.0 at Mangoceuticals, down from $767996.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.2 million in Q1 2025 and bottomed at $30796.0 in Q1 2023.
  • The 3-year median for Accounts Payables is $526964.0 (2025), against an average of $469330.5.
  • The largest YoY upside for Accounts Payables was 3266.23% in 2025 against a maximum downside of 25.52% in 2025.
  • A 3-year view of Accounts Payables shows it stood at $140765.0 in 2023, then surged by 494.96% to $837501.0 in 2024, then plummeted by 37.08% to $526964.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Accounts Payables are $526964.0 (Q3 2025), $767996.0 (Q2 2025), and $1.2 million (Q1 2025).